Literature DB >> 9466588

Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria.

L A Sanni1, S R Thomas, B N Tattam, D E Moore, G Chaudhri, R Stocker, N H Hunt.   

Abstract

The pathogenesis of human cerebral malaria (CM) remains unresolved. In the most widely used murine model of CM, the presence of T lymphocytes and/or interferon (IFN)-gamma is a prerequisite. IFN-gamma is the key inducer of indoleamine 2,3-dioxygenase (IDO), which is the catalyst of the first, and rate-limiting, step in the metabolism of tryptophan (Trp) along the kynurenine (Kyn) pathway. Quinolinic acid (QA), a product of this pathway, is a neuro-excitotoxin, like glutamic acid (Glu) and aspartic acid (Asp). Kynurenic acid (KA), also produced from the Kyn pathway, antagonizes the neuro-excitotoxic effects of QA, Glu, and Asp. We therefore examined the possible roles of IDO, metabolites of the Kyn pathway, Glu, and Asp in the pathogenesis of fatal murine CM. Plasmodium berghei ANKA infection was studied on days 6 and 7 post-inoculation (p.i.), at which time the mice exhibited cerebral symptoms such as convulsions, ataxia, coma, and a positive Wooly/White sign and died within 24 hours. A model for noncerebral malaria (NCM), P. berghei K173 infection, was also studied on days 6 and 7 and 13 to 17 p.i. to examine whether any changes were a general response to malaria infection. Biochemical analyses were done by high-pressure liquid chromatography and gas chromatography/mass spectrometry/mass spectrometry (GC/MS/MS). IDO activity was low or absent in the brains of uninfected mice and NCM mice (days 6 and 7 p.i.) and was induced strongly in the brains of fatal murine CM mice (days 6 and 7 p.i.) and NCM animals (days 13 to 17 p.i.). This induction was inhibited greatly by administration of dexamethasone, a treatment that also prevented CM symptoms and death. Furthermore, IDO induction was absent in IFN-gamma gene knockout mice, which were also resistant to CM. Brain concentrations of Kyn, 3-hydroxykynurenine, and the neuro-excitotoxin QA were significantly increased in both CM mice on days 6 and 7 p.i. and NCM mice on days 13 to 17 p.i., whereas an increase in the ratio of brain QA to KA occurred only in the CM mice at the time they were exhibiting cerebral symptoms. Brain concentrations of Glu and Asp were significantly decreased in CM and NCM mice (days 13 to 17 p.i.). The results imply that neuro-excitation induced by QA may contribute to the convulsions and neuro-excitatory signs observed in CM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466588      PMCID: PMC1857979     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  (18O)quinolinic acid: its esterification without back exchange for use as internal standard in the quantification of brain and CSF quinolinic acid.

Authors:  M P Heyes; S P Markey
Journal:  Biomed Environ Mass Spectrom       Date:  1988-03-01

2.  Fluorimetric micro-determination of kynurenic acid, an endogenous blocker of neurotoxicity, by high-performance liquid chromatography.

Authors:  K Shibata
Journal:  J Chromatogr       Date:  1988-09-09

Review 3.  The pathology of human cerebral malaria.

Authors:  M Aikawa; M Iseki; J W Barnwell; D Taylor; M M Oo; R J Howard
Journal:  Am J Trop Med Hyg       Date:  1990-08       Impact factor: 2.345

4.  Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor.

Authors:  G E Grau; H Heremans; P F Piguet; P Pointaire; P H Lambert; A Billiau; P Vassalli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  The roles of superoxide anion and methylene blue in the reductive activation of indoleamine 2,3-dioxygenase by ascorbic acid or by xanthine oxidase-hypoxanthine.

Authors:  M Sono
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

6.  Release of glutamate and of free fatty acids in vasogenic brain edema.

Authors:  A Baethmann; K Maier-Hauff; L Schürer; M Lange; C Guggenbichler; W Vogt; K Jacob; O Kempski
Journal:  J Neurosurg       Date:  1989-04       Impact factor: 5.115

7.  Increased cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia.

Authors:  M P Heyes; A Lackner
Journal:  J Neurochem       Date:  1990-07       Impact factor: 5.372

8.  Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages.

Authors:  J C Drapier; J Wietzerbin; J B Hibbs
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

9.  Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo.

Authors:  J H Connick; T W Stone
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

10.  Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status.

Authors:  M P Heyes; B J Brew; A Martin; R W Price; A M Salazar; J J Sidtis; J A Yergey; M M Mouradian; A E Sadler; J Keilp
Journal:  Ann Neurol       Date:  1991-02       Impact factor: 10.422

View more
  51 in total

1.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

2.  Early cytokine production is associated with protection from murine cerebral malaria.

Authors:  Andrew J Mitchell; Anna M Hansen; Leia Hee; Helen J Ball; Sarah M Potter; John C Walker; Nicholas H Hunt
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Reactive changes of retinal microglia during fatal murine cerebral malaria: effects of dexamethasone and experimental permeabilization of the blood-brain barrier.

Authors:  I M Medana; T Chan-Ling; N H Hunt
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition.

Authors:  Catherine J Clark; Gillian M Mackay; George A Smythe; Sonia Bustamante; Trevor W Stone; R Stephen Phillips
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 5.  The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways.

Authors:  Riekelt H Houtkooper; Carles Cantó; Ronald J Wanders; Johan Auwerx
Journal:  Endocr Rev       Date:  2009-12-09       Impact factor: 19.871

Review 6.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 7.  The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology.

Authors:  K Artavanis-Tsakonas; J E Tongren; E M Riley
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

8.  Alterations in urine, serum and brain metabolomic profiles exhibit sexual dimorphism during malaria disease progression.

Authors:  Angika Basant; Mayuri Rege; Shobhona Sharma; Haripalsingh M Sonawat
Journal:  Malar J       Date:  2010-04-23       Impact factor: 2.979

9.  Cerebral edema and cerebral hemorrhages in interleukin-10-deficient mice infected with Plasmodium chabaudi.

Authors:  Latifu A Sanni; William Jarra; Ching Li; Jean Langhorne
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  5-Hydroxyanthranilic acid, a tryptophan metabolite, generates oxidative stress and neuronal death via p38 activation in cultured cerebellar granule neurones.

Authors:  Andrew J Smith; Robert A Smith; Trevor W Stone
Journal:  Neurotox Res       Date:  2009-03-04       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.